Ternary Therapeutics

Ternary Therapeutics (TernaryTx) is a UK-based biotechnology company that develops an AI-driven platform for designing molecular glue therapeutics. The company uses computational methods including AI-powered target assessment, geometric deep learning, and molecular dynamics simulations to rationally design molecular glues that can degrade or modulate previously undruggable protein targets. Founded by Dr. Chris Tame, a veteran in AI-driven drug discovery with experience at BenevolentAI and GSK, the team focuses primarily on immunology therapeutic areas including inflammatory and fibrotic diseases, as well as neuroinflammation. The platform enables systematic discovery of molecular glues for targets that lack traditional starting points, addressing diseases with high unmet medical needs beyond oncology. The company operates labs at the Stevenage Bioscience Catalyst with headquarters in London. Programs are currently in preclinical development stages. The company is currently active as a private company, incorporated in October 2024.